



OPEN ACCESS

# Leisure-time physical activity and mortality from influenza and pneumonia: a cohort study of 577 909 US adults

Bryant J Webber ,<sup>1,2</sup> Heather C Yun ,<sup>3</sup> Geoffrey P Whitfield <sup>1</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bjsports-2022-106644>).

<sup>1</sup>Division of Nutrition, Physical Activity and Obesity, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

<sup>2</sup>Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

<sup>3</sup>Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas, USA

## Correspondence to

Dr Bryant J Webber, Division of Nutrition, Physical Activity and Obesity, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA; [rhq0@cdc.gov](mailto:rhq0@cdc.gov)

Accepted 7 March 2023

Published Online First

16 May 2023

## ABSTRACT

**Objective** To examine the association of leisure-time physical activity with mortality from influenza and pneumonia.

**Methods** A nationally representative sample of US adults (aged ≥18 years) who participated in the National Health Interview Survey from 1998 to 2018 were followed for mortality through 2019. Participants were classified as meeting both physical activity guidelines if they reported ≥150 min/week of moderate-intensity equivalent aerobic physical activity and ≥2 episodes/week of muscle-strengthening activity. Participants were also classified into five volume-based categories of self-reported aerobic and muscle-strengthening activity. Influenza and pneumonia mortality was defined as having an underlying cause of death with an International Classification of Diseases, 10th Revision code of J09–J18 recorded in the National Death Index. Mortality risk was assessed using Cox proportional hazards, adjusting for sociodemographic and lifestyle factors, health conditions and influenza and pneumococcal vaccination status. Data were analysed in 2022.

**Results** Among 577 909 participants followed for a median of 9.23 years, 1516 influenza and pneumonia deaths were recorded. Compared with participants meeting neither guideline, those meeting both guidelines had 48% lower adjusted risk of influenza and pneumonia mortality. Relative to no aerobic activity, 10–149, 150–300, 301–600 and >600 min/week were associated with lower risk (by 21%, 41%, 50% and 41%). Relative to <2 episodes/week of muscle-strengthening activity, 2 episodes/week was associated with 47% lower risk and ≥7 episodes/week with 41% higher risk.

**Conclusions** Aerobic physical activity, even at quantities below the recommended level, may be associated with lower influenza and pneumonia mortality while muscle-strengthening activity demonstrated a J-shaped relationship.

## INTRODUCTION

Guidelines from the WHO and US Department of Health and Human Services recommend that adults perform moderate-intensity aerobic physical activity for at least 150 min/week, or vigorous-intensity aerobic physical activity for at least 75 min/week, or an equivalent combination, plus muscle-strengthening activity (MSA) of moderate or greater intensity at least twice per week, to achieve substantial health benefits. According to the guidelines, these benefits include prevention of

## WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ The WHO and US Department of Health and Human Services recommend that adults perform ≥150 min/week of moderate-intensity equivalent aerobic physical activity and ≥2 episodes/week of muscle-strengthening activities.
- ⇒ Physical inactivity is a risk factor for severe COVID-19 illness and potentially for influenza and pneumonia mortality.

## WHAT THIS STUDY ADDS

- ⇒ Among US adults, leisure-time aerobic physical activity was associated with significantly lower risk of influenza and pneumonia mortality, even at an amount below the recommended level.
- ⇒ Two episodes/week of muscle-strengthening activity was associated with lower risk of influenza and pneumonia mortality, whereas ≥7 episodes/week was associated with higher risk.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ Efforts to reduce influenza and pneumonia mortality among adults might focus on decreasing the prevalence of aerobic inactivity and increasing the prevalence of achieving 2 episodes/week of muscle-strengthening activity.

dementia, cardiovascular disease and some cancers; improved physical function and mental health; and greater longevity.<sup>1,2</sup>

Regular physical activity may also protect against infection and mortality from infectious diseases.<sup>3</sup> In their study of leisure-time physical activity and cause-specific mortality among National Health Interview Survey (NHIS) participants from 1997 through 2014, Zhao and colleagues reported that US adults who met the aerobic and muscle-strengthening guidelines had a 54% lower adjusted hazard of influenza and pneumonia mortality, relative to those who met neither guideline.<sup>4</sup> Influenza and pneumonia—which often present concomitantly and are typically grouped by the US National Vital Statistics System<sup>5</sup>—rank in the top 10 causes of death in the USA, before<sup>6</sup> and after<sup>7,8</sup> the emergence of COVID-19.

The objective of this study was to expand on the influenza and pneumonia findings presented by Zhao and colleagues. With a larger population, additional follow-up time, the inclusion of vaccination status and more granular categories of aerobic



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Webber BJ, Yun HC, Whitfield GP. *Br J Sports Med* 2023;**57**:1231–1237.

activity and MSA, we aimed to elucidate the association between the types and amounts of physical activity with influenza and pneumonia mortality risk.

## METHODS

### Study design and data source

This was a longitudinal study of US adults aged  $\geq 18$  years who participated in NHIS from 1998 through 2018. NHIS is an ongoing, cross-sectional household interview survey that captures health information on a representative sample of the civilian, non-institutionalised population of the USA. Using stratified sensitivity analyses and adjustments, we explored the influence of these characteristics, as well as health-related behaviours and baseline health status, on the association between physical activity and influenza and pneumonia mortality. Sample design, interview methodology and data availability details are provided elsewhere.<sup>9</sup>

### Physical activity measurements

To ascertain aerobic leisure-time physical activity, participants were asked how frequently they participated for  $\geq 10$  min in vigorous-intensity activities that caused heavy sweating or large increases in breathing or heart rate and light-intensity or moderate-intensity activities that caused only light sweating or slight to moderate increases in breathing or heart rate. During the study period, NHIS did not distinguish between light-intensity and moderate-intensity aerobic activities. Respondents provided the frequency and duration of each session. MSA was assessed by one question that asked how often the respondent participated in leisure-time physical activities specifically designed to strengthen their muscles, such as lifting weights or performing calisthenics.

Using the customary methodology,<sup>12</sup> we calculated moderate-to-vigorous physical activity (MVPA) min/week as the sum of light-intensity or moderate-intensity aerobic activity min/week plus twice vigorous-intensity aerobic activity min/week. We also calculated MSA episodes/week. We classified participants into four groups based on their adherence to the guidelines: meeting neither guideline ( $<150$  min/week of MVPA and  $<2$  episodes/week of MSA); meeting only the aerobic guideline ( $\geq 150$  min/week of MVPA and  $<2$  episodes/week of MSA); meeting only the muscle-strengthening guideline ( $<150$  min/week of MVPA and  $\geq 2$  episodes/week of MSA) and meeting both guidelines ( $\geq 150$  min/week of MVPA and  $\geq 2$  episodes/week of MSA).

We also classified participants in more detailed physical activity levels. To maximally equalise the distribution of participants while resembling physical activity guideline categories, we defined five levels of aerobic physical activity ( $<10$ , 10–149, 150–300, 301–600 and  $>600$  min/week of MVPA) and muscle-strengthening physical activity ( $<2$ , 2, 3, 4–6 and  $\geq 7$  episodes/week of MSA).

### Covariates

We used the following variables from NHIS: sex; age; race/ethnicity; education; marital status; smoking; alcohol consumption; body mass index (BMI); presence of diagnosed heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease (COPD) and asthma; and influenza and pneumococcal vaccination status.

We classified age as 18–34, 35–49, 50–64, 65–74 and  $\geq 75$  years, and race/ethnicity as non-Hispanic white, non-Hispanic black, Hispanic and non-Hispanic other. We classified education as less than high school, high school graduate or equivalent,

some college or associate's degree and college graduate or higher. We classified marital status as married; divorced, separated or widowed; never married and other. We classified smoking as never ( $<100$  lifetime cigarettes), former ( $\geq 100$  lifetime cigarettes but not currently smoking) and current. We classified alcohol consumption as never ( $<12$  lifetime drinks), former ( $\geq 12$  lifetime drinks but none in previous year), current but not heavy (previous year average  $<8$  drinks/week for women and  $<15$  drinks/week for men) and current heavy ( $\geq 8$  for women and  $\geq 15$  for men). We classified BMI as underweight ( $<18.5$  kg/m<sup>2</sup>), normal (18.5–24.9 kg/m<sup>2</sup>), overweight (25.0–29.9 kg/m<sup>2</sup>), obesity ( $\geq 30.0$  kg/m<sup>2</sup>) and unknown. We dichotomised underlying health conditions as present or absent. Heart disease included coronary heart disease, myocardial infarction, angina and other heart diseases; diabetes included frank diabetes, borderline diabetes and pre-diabetes; COPD included emphysema and chronic bronchitis (COPD was added to NHIS in 2012) and asthma included those with current and previous asthma. We excluded participants with missing data.

NHIS asked participants if they had received an influenza vaccine in the previous 12 months and had ever received a pneumococcal vaccination. We classified participants as yes, no and unknown. We did not distinguish between intramuscular and intranasal influenza vaccination, the latter of which was ascertained from 2004 through 2015.

### Mortality

We obtained mortality outcomes from the 2019 NHIS-National Death Index public-use linked mortality files. We merged survey responses with mortality outcomes using the unique public identification number assigned by National Center for Health Statistics (NCHS). Detailed methodology regarding NHIS linkage to the National Death Index is available elsewhere.<sup>10</sup> For those assumed dead, we attributed mortality to influenza or pneumonia if the underlying cause of death had an *International Classification of Diseases, Injuries, and Causes of Death*, 10th Revision code between J09 and J18. For those assumed alive, we assigned a censoring date of 31 December 2019.<sup>11</sup>

### Population and follow-up time

A total of 611 505 adult NHIS participants were eligible for linkage to the National Death Index.<sup>11</sup> After excluding those with missing physical activity data ( $n=19\ 175$ ) or covariate data ( $n=14\ 421$ ), the final analytic sample was 577 909. For all decedents, we calculated follow-up time as the duration between quarter and year of interview and quarter and year of death. For those assumed alive, we calculated follow-up time as the duration between quarter and year of interview and censoring, per NCHS recommendations.<sup>11</sup>

### Equity, diversity and inclusion statement

Our study sample is designed to be nationally representative, reflecting the demographic, geographic and socioeconomic diversity of the US population. Although small, our author team includes a diversity of disciplines (preventive medicine, infectious diseases and epidemiology) and sex (two men and one woman).

### Statistical analysis

We assessed participant characteristics across strata of physical activity guideline adherence, and we compared the four groups with the Wald  $\chi^2$  test. To determine the association of guideline adherence with influenza and pneumonia mortality—and

the association by aerobic and muscle-strengthening levels—we used weighted Cox proportional hazards regression to calculate HRs with 95% CIs.

Using a directed acyclic graph (online supplemental figure S1), we selected potentially confounding variables and developed two adjusted models. The first model included sex, age, race/ethnicity, education and marital status. The second model added BMI category, smoking status, alcohol consumption, presence or absence of underlying conditions (ie, heart disease, stroke, hypertension, diabetes, cancer, COPD and asthma) and receipt of influenza or pneumococcal vaccine. Age was assessed continuously in both models. To explore the independent effect of aerobic and muscle-strengthening physical activity, we adjusted each activity type for the other.

We performed several sensitivity analyses. First, given the strong correlation between age and mortality, we stratified by select age categories (50–64, 65–74 and  $\geq 75$  years). Second, to address potential reverse causality and confounding by indication, we excluded participants who (1) had an underlying condition at baseline, (2) ever smoked, (3) had an abnormal BMI and (4) died within 2 years of their NHIS interview. Third, to explore the impact of physical activity intensity, we assessed the association of vigorous-intensity aerobic activity with mortality, not doubling the minutes and additionally adjusting for light-intensity and moderate-intensity aerobic physical activity min/week. Finally, we re-analysed MSA using 0 episodes/week as the referent group.

For all analyses, we established significance at a two-sided  $\alpha$  of 0.05, and we verified the proportional hazards assumption using Kaplan-Meier curves and Schoenfeld residuals. To account for the complex survey design and sample weights, we used survey procedures in SAS V9.4 (SAS Institute). The public was not involved in the design, conduct, reporting or dissemination plans of our research.

## RESULTS

### Population characteristics

Of the 577 909 participants, most were women (52.2%) and non-Hispanic white (69.2%). Roughly half (50.5%) did not meet either the aerobic or muscle-strengthening guidelines. Guideline adherence was significantly different by sex, age category, race/ethnicity, education, marital status, smoking status, alcohol consumption, BMI category, presence of each underlying health condition and receipt of influenza or pneumococcal vaccine ( $p < 0.001$  for all) (table 1).

### Physical activity levels and influenza and pneumonia mortality

During a median (SE) of 9.23 (0.01) years of follow-up, 81 431 deaths were recorded, including 1516 deaths attributed to influenza and pneumonia. Compared with participants who met neither physical activity guideline, those who met both guidelines had 48% lower adjusted risk of influenza and pneumonia mortality (HR=0.52; 95%CI: 0.39 to 0.68), and those who met only the aerobic guideline had 36% lower adjusted risk (HR=0.64; 95%CI: 0.54 to 0.76). Meeting only the muscle-strengthening guideline was not associated with a significant difference in mortality (HR=1.16; 95%CI: 0.88 to 1.54) (table 2).

Adjusting for muscle-strengthening category (in addition to sociodemographic and lifestyle factors, underlying conditions and vaccination status), persons who reported MVPA in any category (10–149, 150–300, 301–600 and  $> 600$  min/week)

had lower risk of influenza and pneumonia mortality compared with those who did not report any MVPA, ranging from 21% lower risk for those reporting 10–149 min/week to 50% for those reporting 301–600 min/week (figure 1). Adjusting instead for the aerobic category, persons who reported 2 MSA episodes/week had 47% lower risk of influenza and pneumonia mortality compared with those who reported  $< 2$  episodes/week. The risk was 41% higher among those who reported  $\geq 7$  episodes/week (figure 2).

### Sensitivity analyses

Findings largely held across subpopulations, although some categories lost statistical significance when restricted to select age categories (online supplemental table S1), those without an underlying condition (online supplemental table S2), those who never smoked (online supplemental table S3) and participants with normal BMI (online supplemental table S4). Outcomes remained consistent after excluding the 11 138 participants who died within 2 years of the interview (online supplemental table S5). Compared with participants who reported no vigorous-intensity aerobic physical activity, those who reported 75–150 min/week had 56% lower adjusted mortality risk (online supplemental table S6). Compared with participants who reported no MSA, those with 1 episode/week had a similar adjusted mortality risk (HR=1.09; 95%CI: 0.58 to 2.05) (online supplemental table S7).

## DISCUSSION

In this large US cohort, adults who met the aerobic and muscle-strengthening physical activity guidelines were about half as likely to die from influenza and pneumonia as their peers who met neither guideline. Relative to those who were aerobically inactive, mortality was lower in participants who performed leisure-time aerobic physical activity—even at a level below the recommended minimum of 150 MVPA min/week. Independent of achieving the aerobic guideline, adults who performed 2 MSA episodes/week had lower mortality than those who performed  $< 2$  episodes, while mortality was higher among those who performed  $\geq 7$  episodes.

Our findings largely correspond to and extend those of prior investigations by analysing more detailed categories of aerobic and muscle-strengthening physical activity and by including important confounding variables, such as vaccination status. In an early study, Paffenbarger and colleagues dichotomised 3686 San Francisco longshoremen in 1951 as ‘low energy workers’ (4750–8250 kcal/week of occupational physical activity) or ‘high energy workers’ (8500–10 750 kcal/week). In the following 22 years, the latter group experienced 74% lower adjusted risk of pneumonia mortality ( $p=0.087$ ).<sup>12</sup> Among 24 656 adults who died of natural causes in Hong Kong during the 1998 influenza epidemic (predominantly influenza A subtype H3N2), respiratory and cardiovascular mortality was lower among those who had reported moderate levels of exercise during a baseline health assessment in 1988, compared with those who had reported no exercise.<sup>13</sup> A longitudinal study of 83 165 US women found a 25% lower age-adjusted incidence of community-acquired pneumonia among those in the highest quintile of walking, compared with those in the lowest quintile,<sup>14</sup> and walking appeared protective against pneumonia mortality in a longitudinal study of 110 792 Japanese adults.<sup>15</sup> Zhao and colleagues reported a 54% lower adjusted hazard of influenza and pneumonia mortality among US adults who met both aerobic and muscle-strengthening guidelines, compared with neither.<sup>4</sup>

**Table 1** Baseline characteristics of participants, by physical activity guideline level

	Met neither guideline,* n (weighted %)	Met aerobic only,† n (weighted %)	Met strength only,‡ n (weighted %)	Met both guidelines,§ n (weighted %)	P value
Total	303 227 (50.5)	153 156 (27.2)	20 742 (3.6)	100 784 (18.7)	
Sex					
Male	119 427 (43.4)	70 367 (49.4)	9737 (50.7)	54 454 (57.0)	<0.001
Female	183 800 (56.6)	82 789 (50.6)	11 005 (49.3)	46 330 (43.0)	
Age, years					
18–34	70 709 (26.0)	45 894 (32.1)	5201 (28.9)	40 150 (42.3)	<0.001
35–49	78 319 (27.4)	43 260 (29.2)	5114 (25.9)	29 455 (29.2)	
50–64	74 985 (25.2)	36 448 (23.9)	4919 (24.0)	19 864 (19.5)	
65–74	38 817 (10.9)	17 369 (9.5)	2826 (11.4)	7697 (6.3)	
≥75	40 397 (10.5)	10 185 (5.2)	2682 (9.8)	3618 (2.7)	
Race/ethnicity					
NH white	181 279 (65.9)	104 520 (72.8)	13 498 (69.0)	70 600 (73.2)	<0.001
NH black	48 836 (13.3)	17 273 (9.4)	3154 (13.3)	11 991 (10.7)	
Hispanic	57 357 (15.4)	22 227 (12.1)	2959 (12.0)	12 599 (10.9)	
NH other¶	15 755 (5.5)	9136 (5.7)	1131 (5.7)	5594 (5.2)	
Education					
<High school	71 773 (20.7)	18 765 (11.1)	2873 (12.2)	6090 (6.2)	<0.001
High school	94 818 (32.2)	38 275 (25.4)	5401 (26.6)	17 419 (17.7)	
Some college	82 125 (27.7)	47 868 (31.2)	6801 (32.9)	33 953 (33.5)	
College graduate	54 511 (19.4)	48 248 (32.3)	5667 (28.4)	43 322 (42.7)	
Marital status					
Married	137 388 (55.4)	75 446 (58.3)	8860 (52.7)	44 259 (52.1)	<0.001
DSW	92 318 (20.4)	34 198 (14.1)	6281 (19.7)	19 046 (11.8)	
Never married	57 415 (17.7)	34 487 (20.6)	4586 (21.3)	31 432 (29.0)	
Other**	16 106 (6.5)	9025 (7.0)	1015 (6.3)	6047 (7.1)	
Smoking status					
Never	170 051 (56.3)	88 039 (58.3)	11 705 (58.0)	64 268 (65.2)	<0.001
Former	66 571 (21.7)	35 614 (23.0)	5357 (24.8)	22 424 (21.4)	
Current	66 605 (21.9)	29 503 (18.7)	3680 (17.3)	14 092 (13.3)	
Alcohol consumption					
Never	86 435 (27.3)	27 383 (17.7)	3744 (18.3)	12 034 (12.8)	<0.001
Former	56 804 (17.7)	20 339 (12.4)	3483 (14.9)	9371 (8.6)	
Current, non-heavy	146 567 (50.5)	96 643 (64.3)	12 518 (62.1)	72 899 (72.5)	
Current, heavy	13 421 (4.4)	8791 (5.6)	997 (4.7)	6480 (6.1)	
BMI, kg/m <sup>2</sup>					
<18.5	6523 (2.2)	2331 (1.5)	397 (2.0)	1314 (1.3)	<0.001
18.5–24.9	96 524 (31.8)	56 080 (36.7)	7725 (37.9)	43 442 (42.8)	
25.0–29.9	98 485 (32.5)	53 821 (35.1)	7168 (34.3)	36 310 (36.1)	
≥30.0	91 382 (30.1)	37 472 (24.3)	5074 (24.1)	18 348 (18.4)	
Unknown	10 313 (3.4)	3452 (2.3)	378 (1.7)	1370 (1.3)	
Underlying condition					
Heart disease	46 199 (14.0)	15 770 (9.7)	3153 (13.6)	7896 (7.3)	<0.001
Stroke	12 819 (3.7)	2775 (1.6)	865 (3.4)	1123 (1.0)	<0.001
Hypertension	108 765 (33.2)	41 164 (25.1)	6939 (29.9)	19 456 (17.9)	<0.001
Diabetes	35 262 (10.7)	10 928 (6.6)	2012 (8.6)	3915 (3.6)	<0.001
Cancer	24 901 (7.5)	9910 (6.0)	1826 (7.7)	5016 (4.6)	<0.001
COPD	22 220 (6.8)	6575 (3.9)	1255 (5.4)	2939 (2.7)	<0.001
Asthma	35 853 (11.8)	17 126 (11.2)	2674 (12.5)	12 155 (12.2)	<0.001
Vaccination					
Influenza††	107 012 (34.1)	54 001 (34.3)	8221 (37.4)	34 812 (33.8)	<0.001
Pneumococcal‡‡	68 919 (20.8)	28 695 (17.0)	5489 (23.5)	16 102 (14.6)	<0.001

Sample adults who participated in the National Health Interview Survey from 1998 to 2018 and were eligible for linkage to the National Death Index through 2019 (n=577 909).

\*Reported <150 min/week of moderate-intensity equivalent physical activity and <2 episodes/week of muscle-strengthening activity.

†Reported ≥150 min/week of moderate-intensity equivalent physical activity and <2 episodes/week of muscle-strengthening activity.

‡Reported ≥2 episodes/week of muscle-strengthening activity and <150 min/week of moderate-intensity equivalent physical activity.

§Reported ≥150 min/week of moderate-intensity equivalent physical activity and ≥2 episodes/week of muscle-strengthening activity.

¶Includes persons who identify as non-Hispanic and any of American Indian or Alaska Native, Asian, Native Hawaiian or Pacific Islander or multiracial.

\*\*Living with partner, refused and do not know.

††Reported receiving an influenza vaccination in the prior 12 months.

‡‡Reported ever receiving a pneumococcal vaccine.

BMI, body mass index; COPD, chronic obstructive pulmonary disease; DSW, divorced, separated or widowed; NH, non-Hispanic.



**Table 2** HRs for influenza and pneumonia deaths, by meeting physical activity guidelines

Guideline met	Deaths	Person-years	Unadjusted HR (95% CI)	Adjusted HR* (95% CI)	Adjusted HR† (95% CI)
Neither‡	1128	3 133 418	1.00 (ref)	1.00 (ref)	1.00 (ref)
Aerobic only§	239	1 571 944	0.43 (0.36 to 0.50)	0.60 (0.50 to 0.71)	0.64 (0.54 to 0.76)
Strength only¶	71	208 731	1.00 (0.75 to 1.33)	1.12 (0.85 to 1.49)	1.16 (0.88 to 1.54)
Both**	78	1 016 632	0.20 (0.15 to 0.26)	0.46 (0.35 to 0.61)	0.52 (0.39 to 0.68)

Sample adults who participated in the National Health Interview Survey from 1998 to 2018 and were eligible for linkage to the National Death Index through 2019 (n=577 909).

\*Adjusted for sex, age, race/ethnicity, education and marital status.

†Adjusted for sex; age; race/ethnicity; education; marital status; smoking status; alcohol consumption; body mass index; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease and asthma and influenza and pneumococcal vaccination status.

‡Reported <150 min/week of moderate-intensity equivalent physical activity and <2 episodes/week of muscle-strengthening activity.

§Reported ≥150 min/week of moderate-intensity equivalent physical activity and <2 episodes/week of muscle-strengthening activity.


¶Reported ≥2 episodes/week of muscle-strengthening activity and <150 min/week of moderate-intensity equivalent physical activity.

\*\*Reported ≥150 min/week of moderate-intensity equivalent physical activity and ≥2 episodes/week of muscle-strengthening activity.

By analysing aerobic activity and MSA in more granular categories, our study provides important insights for the prevention of influenza and pneumonia mortality. First, the risk was significantly lower among participants who performed 10–150 min/week of leisure-time MVPA, compared with those who performed none. Although this level is often labelled ‘insufficient’ because it falls below the recommended duration, it may confer health benefits relative to physical inactivity. Previous studies have demonstrated that insufficient aerobic activity, compared with inactivity, is associated with lower overall mortality<sup>16–18</sup> and lower infectious disease mortality,<sup>19 20</sup> including from COVID-19.<sup>21</sup> Second, independent of aerobic activity, mortality risk was significantly lower among participants who performed 2 MSA episodes/week, compared with those who performed <2 episodes/week. At the opposite end, we found that ≥7 MSA episodes/week was associated with an increased risk. A J-shaped dose-response between MSA and all-cause mortality has been


observed elsewhere.<sup>22</sup> While beyond the scope of this study, plausible explanations range from inaccurate responses (such as reporting occupational physical activity, which may not confer the same protective effect as leisure-time physical activity<sup>23</sup>) to haemodynamic ramifications of frequent, high-intensity MSA.<sup>24–26</sup>

The findings of this study are biologically plausible. Physical activity is associated with lower incidence of several comorbidities, including stroke and coronary heart disease,<sup>2</sup> which increase the mortality risk among adults hospitalised with community-acquired pneumonia.<sup>27</sup> Clinical trials have demonstrated that aerobic training programmes improve expectoration in persons with cystic fibrosis<sup>28</sup> and peak oxygen uptake in persons with COPD.<sup>29</sup> In addition to these salutary cardiovascular and pulmonary effects, physical activity has been associated in meta-analyses with a healthier immune profile: increased CD4 cell count (n=24 studies), which may speed the immunologic



Aerobic physical activity	<10 min/wk	10–149 min/wk	150–300 min/wk	301–600 min/wk	>600 min/wk
No. participants (weighted %)	210 358 (34.1)	113 611 (20.0)	86 095 (15.5)	87 243 (15.8)	80 602 (14.7)
Influenza and pneumonia deaths	926	273	139	92	86
Person-years	2 181 939	1 160 211	886 899	886 438	815 239
Adjusted hazard ratio (95% CI)	1.00 [reference]	0.79 (0.67 to 0.93)	0.59 (0.48 to 0.72)	0.50 (0.39 to 0.66)	0.59 (0.43 to 0.80)

**Figure 1** Adjusted HRs (95% CI) for influenza and pneumonia mortality based on weekly min of moderate-intensity equivalent aerobic physical activity. Adjusted for sex; age; race/ethnicity; education; marital status; smoking status; alcohol consumption; body mass index; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease and asthma; influenza and pneumococcal vaccination status and muscle-strengthening activity category. Based on sample adults who participated in the National Health Interview Survey from 1998 to 2018 and were eligible for linkage to the National Death Index through 2019 (n=577 909).



**Figure 2** Adjusted HRs (95% CI) for influenza and pneumonia mortality based on weekly episodes of muscle-strengthening activity. Adjusted for sex; age; race/ethnicity; education; marital status; smoking status; alcohol consumption; body mass index; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease and asthma; influenza and pneumococcal vaccination status and aerobic physical activity category. Based on sample adults who participated in the National Health Interview Survey from 1998 to 2018 and were eligible for linkage to the National Death Index through 2019 (n=577 909).

response to microbes and sustain the memory thereof<sup>3</sup>; increased salivary immunoglobulin A concentration (n=7 studies), which may strengthen mucosal defenses<sup>3</sup>; and decreased levels of C reactive protein (n=7 studies) and interleukin-6 (n=5 studies), which may reduce chronic inflammation and its negative immunomodulatory effects.<sup>30</sup> Acute bouts of moderate-intensity physical activity are also associated with transient improvements in innate and adaptive immune cells, including natural killer and highly cytotoxic T lymphocytes and immature B cells. These transient immunologic benefits may accumulate over time<sup>31</sup> and acquire a magnified importance at older ages, perhaps through the mediating impact of physical activity on telomere shortening and immunosenescent processes.<sup>32</sup>

Regular physical activity may also enhance the immune response to vaccination. In a recent meta-analysis, habitual aerobic physical activity level was positively correlated with antibody titers following influenza vaccination, but not pneumococcal vaccination.<sup>33</sup> Evidence for physical activity as an acute vaccine adjuvant is more tenuous, although this may reflect intervention heterogeneity in clinical trials. For example, older adults randomised to a 10-month aerobic activity programme prior to influenza vaccination sustained seroprotection for a longer duration than those randomised to a flexibility and balance programme.<sup>34</sup> In another trial, a brisk 45-minute walk before influenza and pneumococcal vaccine did not affect antibody response.<sup>35</sup> Analysed collectively, trial data suggest that single-session physical activity interventions have no impact on vaccine response, whereas those exceeding 2 weeks enhance post-vaccination influenza titers.<sup>33</sup>

### Strengths and limitations

This study benefits from a large and nationally representative sample, granular leisure-time physical activity data and prolonged

follow-up, but it has some limitations. First, exposure data were self-reported at a single time point. These data are susceptible to recall and social desirability biases.<sup>36 37</sup> Exposure status may have also changed during the follow-up period, although some health behaviours, including annual influenza vaccination,<sup>38</sup> are often consistent over time. Second, NHIS inquired about leisure-time physical activity in bouts of ≥10 min; it did not capture other domains or shorter episodes of physical activity, despite these counting toward the aerobic guideline, and it did not distinguish between light-intensity and moderate-intensity activity.<sup>1 2</sup> Third, dichotomous classification of underlying conditions in NHIS prevents analysis of disease severity, which may be associated with physical activity participation and mortality. Fourth, we obtained outcomes from the public-use linked mortality files, which are less complete than the restricted-use files to protect participant privacy.<sup>11</sup> However, the public-use and restricted-use files generate similar HRs for influenza and pneumonia mortality by several sociodemographic factors.<sup>39</sup> Finally, individuals may alter their physical activity based on underlying conditions. Although we cannot dismiss reverse causality and confounding by indication, we are reassured by the consistency of our findings across primary and sensitivity analyses.

### Clinical and public health implications

This study has at least two clinical implications. First, the mortality benefit associated with ‘insufficient’ aerobic physical activity and with 2 MSA episodes/week might provide additional justification for healthcare providers to promote physical activity among their inactive patients. These potentially achievable targets are relevant to large segments of the population: 34.1% of the weighted sample were aerobically inactive, and 77.7% reported <2 MSA episodes/week. Second, given the increased

mortality risk among those reporting  $\geq 7$  MSA episodes/week, clinical decision tools related to physical activity screening may want to flag very high levels of MSA, in addition to levels below guidelines.

Although the outcome was influenza and pneumonia mortality, the pathophysiologic principles may apply to COVID-19 and other infectious respiratory diseases. Consistent with this finding, the Centers for Disease Control and Prevention, based on a review of 25 studies, concluded that physical inactivity is an independent risk factor for severe COVID-19 illness.<sup>40</sup> In one of the largest studies, patients who were physically inactive before COVID-19 diagnosis had greater odds of hospitalisation (OR=2.26) and death (OR=2.49) than their peers who consistently met the aerobic guideline—ORs exceeding those of smoking, severe obesity and metastatic cancer history.<sup>41</sup>

Current physical activity guidelines emphasise prevention of non-communicable diseases.<sup>1 2</sup> When updated, these guidelines may wish to reflect the emerging body of evidence demonstrating an association between physical activity and lower mortality from infectious diseases.

## CONCLUSION

Among 577 K US adults followed for a median of 9.2 years, meeting both the aerobic and muscle-strengthening guidelines was associated with nearly half the risk of influenza and pneumonia mortality, compared with meeting neither guideline. Aerobic physical activity was associated with lower risk of influenza and pneumonia mortality, even at amounts below the guideline recommendation, whereas MSA displayed a J-shaped dose-response. Considering the plausible biological mechanisms and the consistency with previous studies, this protective association may warrant additional clinical and public health efforts to decrease the prevalence of aerobic inactivity and inadequate MSA.

**Acknowledgements** Thanks to Kelsey M Sumner, PhD, for reviewing our analytic plan.

**Contributors** All authors conceived of the study design and approach. BJW and GW constructed the cohort from the National Health Interview Survey and conducted the primary statistical analyses. All authors contributed to initial drafting of the manuscript, interpretation of the results, manuscript presentation, critical revisions of the manuscript, and final approval to submit the manuscript for publication. BJW is the guarantor and accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Disclaimer** The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the Department of Defense or the US government.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by Ethics Review Board of the National Center for Health Statistics (NCHS). Participants provided verbal consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open access repository. All data used in this study are publicly available through the National Center for Health Statistics at <https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm> and <https://www.cdc.gov/nchs/data-linkage/mortality-public.htm>.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those

of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Bryant J Webber <http://orcid.org/0000-0002-2099-2671>

Heather C Yun <http://orcid.org/0000-0001-6173-3169>


Geoffrey P Whitfield <http://orcid.org/0000-0002-3991-8690>

## REFERENCES

- 1 WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization, 2020.
- 2 U.S. Department of Health and Human Services. *Physical activity guidelines for americans*. 2nd ed. Washington, DC: U.S. Department of Health and Human Services, 2018.
- 3 Chastin SFM, Abaraogu U, Bourgois JG, et al. Effects of regular physical activity on the immune system, vaccination and risk of community-acquired infectious disease in the general population: systematic review and meta-analysis. *Sports Med* 2021;51:1673–86.
- 4 Zhao M, Veeranki SP, Magnussen CG, et al. Recommended physical activity and all cause and cause specific mortality in US adults: prospective cohort study. *BMJ* 2020;370:m2031.
- 5 Anderson RN, Miniño AM, Hoyert DL, et al. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. *Natl Vital Stat Rep* 2001;49:1–32.
- 6 Kochanek KD, Xu J, Arias E. *Mortality in the United States, 2019*. NCHS data brief no 395. 2020.
- 7 Murphy SL, Kochanek KD, Xu J, et al. *Mortality in the United States, 2020*. NCHS data brief no 427. 2021.
- 8 Ahmad FB, Cisevski JA, Anderson RN. Provisional mortality data—United States, 2021. *MMWR Morb Mortal Wkly Rep* 2022;71:597–600.
- 9 National Center for Health Statistics. About the national health interview survey. 2022. Available: [https://www.cdc.gov/nchs/nhis/about\\_nhis.htm](https://www.cdc.gov/nchs/nhis/about_nhis.htm)
- 10 National Center for Health Statistics. The linkage of national center for health statistics survey data to the national death index – 2019 Linked Mortality File (LMF): linkage methodology and analytic considerations. 2021. Available: <https://www.cdc.gov/nchs/data/datalinkage/2019NDI-Linkage-Methods-and-Analytic-Considerations-508.pdf>
- 11 National Center for Health Statistics. Public-use linked mortality files. 2022. Available: <https://www.cdc.gov/nchs/data/datalinkage/public-use-linked-mortality-file-description.pdf>
- 12 Paffenbarger RS, Brand RJ, Sholtz RI, et al. Energy expenditure, cigarette smoking, and blood pressure level as related to death from specific diseases. *Am J Epidemiol* 1978;108:12–8.
- 13 Wong C-M, Lai H-K, Ou C-Q, et al. Is exercise protective against influenza-associated mortality? *PLoS One* 2008;3:e2108.
- 14 Neuman MI, Willett WC, Curhan GC. Physical activity and the risk of community-acquired pneumonia in US women. *Am J Med* 2010;123:281.
- 15 Inoue Y, Koizumi A, Wada Y, et al. Risk and protective factors related to mortality from pneumonia among middleaged and elderly community residents: the JACC Study. *J Epidemiol* 2007;17:194–202.
- 16 Schoenborn CA, Stommel M. Adherence to the 2008 adult physical activity guidelines and mortality risk. *Am J Prev Med* 2011;40:514–21.
- 17 Coleman CJ, McDonough DJ, Pope ZC, et al. Dose-response association of aerobic and muscle-strengthening physical activity with mortality: a national cohort study of 416 420 US adults. *Br J Sports Med* 2022;56:1218–23.
- 18 Arem H, Moore SC, Patel A, et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. *JAMA Intern Med* 2015;175:959–67.
- 19 Hamer M, O'Donovan G, Stamatakis E. Lifestyle risk factors, obesity and infectious disease mortality in the general population: linkage study of 97,844 adults from England and Scotland. *Prev Med* 2019;123:65–70.
- 20 Lee SW, Lee J, Moon SY, et al. Physical activity and the risk of SARS-CoV-2 infection, severe COVID-19 illness and COVID-19 related mortality in South Korea: a nationwide cohort study. *Br J Sports Med* 2022;56:901–12.
- 21 Ezzatvar Y, Ramirez-Vélez R, Izquierdo M, et al. Physical activity and risk of infection, severity and mortality of COVID-19: a systematic review and non-linear dose-response meta-analysis of data from 1 853 610 adults. *Br J Sports Med* 2022;bjsports-2022-105733.

- 22 Shailendra P, Baldock KL, Li LSK, *et al.* Resistance training and mortality risk: a systematic review and meta-analysis. *Am J Prev Med* 2022;63:277–85.
- 23 Samitz G, Egger M, Zwahlen M. Domains of physical activity and all-cause mortality: systematic review and dose-response meta-analysis of cohort studies. *Int J Epidemiol* 2011;40:1382–400.
- 24 Miyachi M, Donato AJ, Yamamoto K, *et al.* Greater age-related reductions in central arterial compliance in resistance-trained men. *Hypertension* 2003;41:130–5.
- 25 Miyachi M, Kawano H, Sugawara J, *et al.* Unfavorable effects of resistance training on central arterial compliance: a randomized intervention study. *Circulation* 2004;110:2858–63.
- 26 Lamotte M, Niset G, van de Borne P. The effect of different intensity modalities of resistance training on beat-to-beat blood pressure in cardiac patients. *Eur J Cardiovasc Prev Rehabil* 2005;12:12–7.
- 27 Waterer GW, Self WH, Courtney DM, *et al.* In-hospital deaths among adults with community-acquired pneumonia. *Chest* 2018;154:628–35.
- 28 Dwyer TJ, Alison JA, McKeough ZJ, *et al.* Effects of exercise on respiratory flow and sputum properties in patients with cystic fibrosis. *Chest* 2011;139:870–7.
- 29 Leite MR, Ramos EMC, Kalva-Filho CA, *et al.* Effects of 12 weeks of aerobic training on autonomic modulation, mucociliary clearance, and aerobic parameters in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2015;10:2549–57.
- 30 Monteiro-Junior RS, de Tarso Maciel-Pinheiro P, da Matta Mello Portugal E, *et al.* Effect of exercise on inflammatory profile of older persons: systematic review and meta-analyses. *J Phys Act Health* 2018;15:64–71.
- 31 Nieman DC, Wentz LM. The compelling link between physical activity and the body's defense system. *J Sport Health Sci* 2019;8:201–17.
- 32 Domaszewska K, Boraczyński M, Tang Y-Y, *et al.* Protective effects of exercise become especially important for the aging immune system in the COVID-19 era. *Aging Dis* 2022;13:129–43.
- 33 Dinas PC, Koutedakis Y, Ioannou LG, *et al.* Effects of exercise and physical activity levels on vaccination efficacy: a systematic review and meta-analysis. *Vaccines (Basel)* 2022;10:769.
- 34 Woods JA, Keylock KT, Lowder T, *et al.* Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: the immune function intervention trial. *J Am Geriatr Soc* 2009;57:2183–91.
- 35 Long JE, Ring C, Drayson M, *et al.* Vaccination response following aerobic exercise: can a brisk walk enhance antibody response to pneumococcal and influenza vaccinations? *Brain Behav Immun* 2012;26:680–7.
- 36 Tucker JM, Welk GJ, Beyler NK. Physical activity in U.S.: adults compliance with the physical activity guidelines for Americans. *Am J Prev Med* 2011;40:454–61.
- 37 Adams SA, Matthews CE, Ebbeling CB, *et al.* The effect of social desirability and social approval on self-reports of physical activity. *Am J Epidemiol* 2005;161:389–98.
- 38 Walsh MM, Parker AM, Vardavas R, *et al.* The stability of influenza vaccination behavior over time: a longitudinal analysis of individuals across 8 years. *Ann Behav Med* 2020;54:783–93.
- 39 Mirel LB, El Bural Félix S, Zhang C, *et al.* Comparative analysis of the National health interview survey public-use and restricted-use linked mortality files. *Natl Health Stat Report* 2020:1–32.
- 40 Hill A, Whitfield G, *et al.* Centers for Disease Control and Prevention. Brief summary of findings on the association between physical inactivity and severe COVID-19 outcomes. 2021. Available: <https://www.cdc.gov/coronavirus/2019-ncov/downloads/clinical-care/E-Physical-Inactivity-Review.pdf>
- 41 Sallis R, Young DR, Tartof SY, *et al.* Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. *Br J Sports Med* 2021;55:1099–105.





**Figure S1.** Directed acyclic graph depicting potential causal and non-causal pathways between physical activity and influenza and pneumonia mortality.

**Table S1. Hazard Ratios for Influenza and Pneumonia Deaths, by Physical Activity Levels, Stratified by Age Groups**

	50–64 Years (n=136 216)		65–74 Years (n=66 709)		≥75 Years (n=56 882)	
	Deaths	aHR <sup>a</sup> (95% CI)	Deaths	aHR <sup>a</sup> (95% CI)	Deaths	aHR <sup>a</sup> (95% CI)
Guideline						
Neither <sup>b</sup>	181	1.00 [ref]	233	1.00 [ref]	626	1.00 [ref]
Aerobic only <sup>c</sup>	34	0.51 (0.32 to 0.80)	57	0.59 (0.42 to 0.82)	122	0.69 (0.54 to 0.88)
Strength only <sup>d</sup>	9	1.04 (0.46 to 2.34)	11	0.88 (0.41 to 1.90)	41	1.27 (0.88 to 1.85)
Both <sup>e</sup>	10	0.39 (0.19 to 0.81)	20	0.58 (0.35 to 0.97)	34	0.53 (0.35 to 0.79)
MVPA, min/wk						
<10	147	1.00 [ref]	197	1.00 [ref]	514	1.00 [ref]
10–149	43	0.88 (0.58 to 1.34)	47	0.58 (0.38 to 0.86)	153	0.85 (0.69 to 1.04)
150–300	19	0.52 (0.29 to 0.93)	29	0.47 (0.30 to 0.73)	79	0.70 (0.54 to 0.90)
301–600	11	0.34 (0.17 to 0.68)	26	0.56 (0.32 to 0.97)	40	0.45 (0.31 to 0.64)
>600	14	0.55 (0.26 to 1.20)	22	0.46 (0.28 to 0.76)	37	0.65 (0.41 to 1.03)
MSA, episodes/wk						
<2	215	1.00 [ref]	290	1.00 [ref]	748	1.00 [ref]
2	2	0.32 (0.08 to 1.33)	4	0.53 (0.19 to 1.52)	8	0.57 (0.27 to 1.18)
3	6	0.79 (0.32 to 1.97)	10	1.16 (0.57 to 2.35)	18	0.99 (0.56 to 1.75)
4–6	0	--	10	1.78 (0.81 to 3.92)	7	0.62 (0.27 to 1.42)
≥7	11	1.97 (0.91 to 4.25)	7	0.72 (0.33 to 1.58)	42	1.45 (0.99 to 2.12)

aHR, adjusted hazard ratio; MSA, muscle-strengthening activity; MVPA, moderate-to-vigorous physical activity.

Sample adults ≥50 years who participated in the National Health Interview Survey from 1998–2018 and were eligible for linkage to the National Death Index through 2019.

<sup>a</sup>Adjusted for sex; race/ethnicity; education; marital status; smoking status; alcohol consumption; body mass index; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease, and asthma; and influenza and pneumococcal vaccination status. Aerobic categories are also adjusted for muscle-strengthening categories and vice versa.

<sup>b</sup>Reported <150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>c</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>d</sup>Reported ≥2 episodes/wk of muscle-strengthening activity and <150 min/wk of moderate-intensity equivalent physical activity.

<sup>e</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and ≥2 episodes/wk of muscle-strengthening activity.

**Table S2. Hazard Ratios for Influenza and Pneumonia Deaths, by Physical Activity Levels, Restricted to Those Without Any Baseline Medical Conditions**

	Deaths	No. (weighted %)	Person- Years	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	Adjusted HR <sup>b</sup> (95% CI)
Guideline						
Neither <sup>c</sup>	248	143 954 (46.0)	1 692 388	1.00 [ref]	1.00 [ref]	1.00 [ref]
Aerobic only <sup>d</sup>	65	85 473 (28.6)	935 412	0.43 (0.31 to 0.59)	0.55 (0.40 to 0.76)	0.56 (0.37 to 0.85)
Strength only <sup>e</sup>	17	10 082 (3.4)	115 422	0.91 (0.52 to 1.59)	1.09 (0.62 to 1.90)	1.02 (0.49 to 2.09)
Both <sup>f</sup>	26	63 604 (22.0)	671 672	0.25 (0.16 to 0.41)	0.53 (0.32 to 0.88)	0.62 (0.29 to 1.35)
MVPA, min/wk						
<10	209	97 601 (30.4)	1 172 197	1.00 [ref]	1.00 [ref]	1.00 [ref]
10–149	56	56 435 (19.0)	635 613	0.51 (0.36 to 0.72)	0.68 (0.47 to 0.98)	0.59 (0.36 to 0.96)
150–300	40	48 054 (16.3)	529 713	0.35 (0.24 to 0.52)	0.55 (0.37 to 0.82)	0.49 (0.29 to 0.85)
301–600	24	51 946 (17.6)	556 921	0.25 (0.15 to 0.40)	0.41 (0.25 to 0.69)	0.43 (0.21 to 0.87)
>600	27	49 077 (16.7)	520 450	0.28 (0.17 to 0.45)	0.45 (0.27 to 0.76)	0.42 (0.18 to 0.98)
MSA, episodes/wk						
<2	313	229 427 (74.6)	2 627 800	1.00 [ref]	1.00 [ref]	1.00 [ref]
2	4	17 720 (6.1)	187 679	0.18 (0.06 to 0.49)	0.51 (0.18 to 1.47)	0.91 (0.26 to 3.18)
3	18	25 139 (8.7)	277 393	0.65 (0.38 to 1.13)	1.69 (0.97 to 2.94)	1.48 (0.44 to 4.98)
4–6	5	17 711 (6.2)	183 673	0.13 (0.05 to 0.38)	0.43 (0.15 to 1.26)	1.01 (0.40 to 2.54)
≥7	16	13 116 (4.4)	138 349	0.80 (0.45 to 1.41)	1.20 (0.66 to 2.17)	1.17 (0.57 to 2.37)

HR, hazard ratio; MSA, muscle-strengthening activity; MVPA, moderate-to-vigorous physical activity.

Sample adults who participated in the National Health Interview Survey from 1998–2018 and were eligible for linkage to the National Death Index through 2019. Restricted to those without baseline presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease, or asthma (N=303 113).

<sup>a</sup>Adjusted for sex, age, race/ethnicity, education, and marital status. Aerobic categories are also adjusted for muscle-strengthening categories and vice versa.

<sup>b</sup>Adjusted for sex, age, race/ethnicity, education, marital status, smoking status, alcohol consumption, body mass index, and influenza and pneumococcal vaccination status. Aerobic categories are also adjusted for muscle-strengthening categories and vice versa.

<sup>c</sup>Reported <150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>d</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>e</sup>Reported ≥2 episodes/wk of muscle-strengthening activity and <150 min/wk of moderate-intensity equivalent physical activity.

<sup>f</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and ≥2 episodes/wk of muscle-strengthening activity.

**Table S3. Hazard Ratios for Influenza and Pneumonia Deaths, by Physical Activity Levels, Restricted to Never Smokers**

	Deaths	No. (weighted %)	Person- Years	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	Adjusted HR <sup>b</sup> (95% CI)
Guideline						
Neither <sup>c</sup>	571	170 051 (48.5)	1 794 912	1.00 [ref]	1.00 [ref]	1.00 [ref]
Aerobic only <sup>d</sup>	122	88 039 (27.1)	894 531	0.44 (0.35 to 0.56)	0.69 (0.54 to 0.88)	0.73 (0.57 to 0.94)
Strength only <sup>e</sup>	24	11 705 (3.5)	119 419	1.34 (0.88 to 2.05)	0.67 (0.42 to 1.09)	0.71 (0.44 to 1.15)
Both <sup>f</sup>	34	64 268 (20.8)	632 766	0.16 (0.11 to 0.23)	0.44 (0.29 to 0.65)	0.48 (0.33 to 0.72)
MVPA, min/wk						
<10	481	115 830 (32.0)	1 235 454	1.00 [ref]	1.00 [ref]	1.00 [ref]
10–149	114	65 926 (20.1)	678 877	0.38 (0.31 to 0.48)	0.60 (0.47 to 0.75)	0.63 (0.50 to 0.80)
150–300	72	52 365 (16.3)	535 044	0.32 (0.24 to 0.42)	0.63 (0.47 to 0.84)	0.67 (0.50 to 0.90)
301–600	47	53 052 (16.7)	531 173	0.21 (0.15 to 0.29)	0.52 (0.36 to 0.76)	0.56 (0.39 to 0.81)
>600	37	46 890 (14.9)	461 080	0.23 (0.15 to 0.36)	0.62 (0.38 to 0.99)	0.68 (0.43 to 1.09)
MSA, episodes/wk						
<2	693	258 090 (75.7)	2 689 443	1.00 [ref]	1.00 [ref]	1.00 [ref]
2	9	18 444 (5.9)	182 334	0.15 (0.08 to 0.31)	0.50 (0.24 to 1.01)	0.52 (0.26 to 1.06)
3	14	25 844 (8.3)	263 660	0.21 (0.11 to 0.39)	0.61 (0.32 to 1.16)	0.64 (0.34 to 1.22)
4–6	5	17 999 (5.9)	175 396	0.14 (0.05 to 0.35)	0.46 (0.18 to 1.18)	0.48 (0.19 to 1.21)
≥7	30	13 686 (4.3)	130 795	0.76 (0.52 to 1.13)	1.00 (0.67 to 1.52)	1.00 (0.66 to 1.51)

HR, hazard ratio; MSA, muscle-strengthening activity; MVPA, moderate-to-vigorous physical activity.

Sample adults who participated in the National Health Interview Survey from 1998–2018 and were eligible for linkage to the National Death Index through 2019. Restricted to those who reported never smoking (N=334 063).

<sup>a</sup>Adjusted for sex, age, race/ethnicity, education, and marital status. Aerobic categories are also adjusted for muscle-strengthening categories and vice versa.

<sup>b</sup>Adjusted for sex; age; race/ethnicity; education; marital status; alcohol consumption; body mass index; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease, and asthma; and influenza and pneumococcal vaccination status. Aerobic categories are also adjusted for muscle-strengthening categories and vice versa.

<sup>c</sup>Reported <150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>d</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>e</sup>Reported ≥2 episodes/wk of muscle-strengthening activity and <150 min/wk of moderate-intensity equivalent physical activity.

<sup>f</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and ≥2 episodes/wk of muscle-strengthening activity.



**Table S4. Hazard Ratios for Influenza and Pneumonia Deaths, by Physical Activity Levels, Restricted to Participants with Normal Body Mass Index at Baseline**

	Deaths	No. (weighted %)	Person- Years	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	Adjusted HR <sup>b</sup> (95% CI)
Guideline						
Neither <sup>c</sup>	423	96 524 (45.3)	1 033 430	1.00 [ref]	1.00 [ref]	1.00 [ref]
Aerobic only <sup>d</sup>	118	56 080 (28.3)	598 886	0.52 (0.42 to 0.65)	0.77 (0.61 to 0.98)	0.83 (0.65 to 1.06)
Strength only <sup>e</sup>	35	7725 (3.8)	82 511	1.13 (0.75 to 1.69)	1.31 (0.88 to 1.95)	1.40 (0.94 to 2.09)
Both <sup>f</sup>	37	43 442 (22.6)	454 761	0.20 (0.14 to 0.30)	0.53 (0.36 to 0.77)	0.61 (0.41 to 0.91)
MVPA, min/wk						
<10	350	66 885 (30.5)	712 422	1.00 [ref]	1.00 [ref]	1.00 [ref]
10–149	108	37 364 (18.6)	403 520	0.52 (0.41 to 0.67)	0.77 (0.60 to 0.98)	0.82 (0.64 to 1.05)
150–300	69	31 741 (16.1)	343 469	0.38 (0.29 to 0.49)	0.68 (0.52 to 0.90)	0.74 (0.56 to 0.98)
301–600	44	34 948 (17.9)	369 811	0.25 (0.18 to 0.36)	0.56 (0.38 to 0.81)	0.61 (0.42 to 0.90)
>600	42	32 833 (16.9)	340 366	0.30 (0.20 to 0.44)	0.67 (0.43 to 1.04)	0.74 (0.48 to 1.16)
MSA, episodes/wk						
<2	541	152 604 (73.6)	1 632 315	1.00 [ref]	1.00 [ref]	1.00 [ref]
2	10	12 101 (6.2)	127 321	0.21 (0.11 to 0.41)	0.66 (0.34 to 1.31)	0.72 (0.37 to 1.42)
3	18	17 310 (9.0)	187 472	0.34 (0.20 to 0.59)	0.91 (0.53 to 1.57)	0.97 (0.56 to 1.68)
4–6	10	11 674 (6.2)	120 510	0.27 (0.13 to 0.55)	0.82 (0.40 to 1.71)	0.90 (0.43 to 1.88)
≥7	34	10 082 (5.0)	101 970	1.01 (0.67 to 1.51)	1.25 (0.81 to 1.91)	1.30 (0.85 to 2.00)

HR, hazard ratio; MSA, muscle-strengthening activity; MVPA, moderate-to-vigorous physical activity.

Sample adults who participated in the National Health Interview Survey from 1998–2018 and were eligible for linkage to the National Death Index through 2019. Restricted to those who reported body mass index in the normal range (N=203 771).

<sup>a</sup>Adjusted for sex, age, race/ethnicity, education, and marital status. Aerobic categories are also adjusted for muscle-strengthening categories and vice versa.

<sup>b</sup>Adjusted for sex; age; race/ethnicity; education; marital status; smoking status; alcohol consumption; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease, and asthma; and influenza and pneumococcal vaccination status. Aerobic categories are also adjusted for muscle-strengthening categories and vice versa.

<sup>c</sup>Reported <150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>d</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>e</sup>Reported ≥2 episodes/wk of muscle-strengthening activity and <150 min/wk of moderate-intensity equivalent physical activity.

<sup>f</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and ≥2 episodes/wk of muscle-strengthening activity.

**Table S5. Hazard Ratios for Influenza and Pneumonia Deaths, by Physical Activity Levels, Excluding Those Who Died Within Two Years of the Interview**

	Deaths	No. (weighted %)	Person- Years	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	Adjusted HR <sup>b</sup> (95% CI)
Guideline						
Neither <sup>c</sup>	1001	294 377 (50.0)	3 124 774	1.00 [ref]	1.00 [ref]	1.00 [ref]
Aerobic only <sup>d</sup>	222	151 837 (27.5)	1 570 564	0.45 (0.38 to 0.53)	0.61 (0.51 to 0.72)	0.65 (0.55 to 0.78)
Strength only <sup>e</sup>	65	20 246 (3.6)	208 243	1.05 (0.78 to 1.42)	1.18 (0.88 to 1.59)	1.23 (0.92 to 1.66)
Both <sup>f</sup>	71	100 311 (18.9)	1 016 147	0.21 (0.16 to 0.28)	0.47 (0.35 to 0.63)	0.53 (0.39 to 0.71)
MVPA, min/wk						
<10	817	202 717 (33.5)	2 174 582	1.00 [ref]	1.00 [ref]	1.00 [ref]
10–149	249	111 906 (20.1)	1 158 435	0.56 (0.47 to 0.67)	0.76 (0.64 to 0.91)	0.82 (0.68 to 0.97)
150–300	126	85 327 (15.6)	886 108	0.35 (0.28 to 0.43)	0.55 (0.45 to 0.69)	0.60 (0.48 to 0.75)
301–600	86	86 675 (16.0)	885 849	0.25 (0.19 to 0.32)	0.46 (0.35 to 0.61)	0.51 (0.39 to 0.67)
>600	81	80 146 (14.9)	814 754	0.29 (0.22 to 0.39)	0.54 (0.39 to 0.74)	0.60 (0.44 to 0.83)
MSA, episodes/wk						
<2	1223	446 214 (77.5)	4 695 338	1.00 [ref]	1.00 [ref]	1.00 [ref]
2	15	28 344 (5.3)	285 740	0.17 (0.10 to 0.29)	0.47 (0.28 to 0.82)	0.50 (0.29 to 0.86)
3	37	40 732 (7.6)	426 621	0.38 (0.26 to 0.55)	0.96 (0.65 to 1.42)	1.02 (0.69 to 1.49)
4–6	16	27 389 (5.2)	273 089	0.22 (0.13 to 0.38)	0.66 (0.37 to 1.17)	0.69 (0.39 to 1.22)
≥7	68	24 092 (4.3)	238 940	1.12 (0.85 to 1.49)	1.52 (1.13 to 2.04)	1.51 (1.12 to 2.03)

HR, hazard ratio; MSA, muscle-strengthening activity; MVPA, moderate-to-vigorous physical activity.

Sample adults who participated in the National Health Interview Survey from 1998–2018 and were eligible for linkage to the National Death Index through 2019. Restricted to those who did not die within 2 years of the NHIS interview (N=566 771).

<sup>a</sup>Adjusted for sex, age, race/ethnicity, education, and marital status. Aerobic categories are also adjusted for muscle-strengthening categories and vice versa.

<sup>b</sup>Adjusted for sex; age; race/ethnicity; education; marital status; smoking status; alcohol consumption; body mass index; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease, and asthma; and influenza and pneumococcal vaccination status. Aerobic categories are also adjusted for muscle-strengthening categories and vice versa.

<sup>c</sup>Reported <150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>d</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and <2 episodes/wk of muscle-strengthening activity.

<sup>e</sup>Reported ≥2 episodes/wk of muscle-strengthening activity and <150 min/wk of moderate-intensity equivalent physical activity.

<sup>f</sup>Reported ≥150 min/wk of moderate-intensity equivalent physical activity and ≥2 episodes/wk of muscle-strengthening activity.

**Table S6. Hazard Ratios for Influenza and Pneumonia Deaths, by Vigorous-Intensity Aerobic Physical Activity**

VPA (min/wk)	Deaths	No. (weighted %)	Person-Years	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	Adjusted HR <sup>b</sup> (95% CI)	Adjusted HR <sup>c</sup> (95% CI)
<10	1316	343 035 (56.6)	3 496 996	1.00 [ref]	1.00 [ref]	1.00 [ref]	1.00 [ref]
10–74	76	68 231 (12.7)	718 826	0.29 (0.22 to 0.38)	0.79 (0.60 to 1.04)	0.87 (0.66 to 1.15)	0.88 (0.67 to 1.17)
75–150	41	62 010 (11.5)	650 634	0.15 (0.11 to 0.22)	0.40 (0.28 to 0.57)	0.44 (0.30 to 0.63)	0.44 (0.31 to 0.64)
>150	83	104 633 (19.2)	1 064 270	0.20 (0.15 to 0.26)	0.48 (0.36 to 0.63)	0.53 (0.40 to 0.69)	0.54 (0.41 to 0.72)

HR, hazard ratio; VPA, vigorous-intensity physical activity.

Sample adults who participated in the National Health Interview Survey from 1998–2018 and were eligible for linkage to the National Death Index through 2019 (N=577 909).

<sup>a</sup>Adjusted for sex, age, race/ethnicity, education, marital status, and muscle-strengthening category.

<sup>b</sup>Adjusted for sex; age; race/ethnicity; education; marital status; muscle-strengthening category; smoking status; alcohol consumption; body mass index; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease, and asthma; and influenza and pneumococcal vaccination status.

<sup>c</sup>Adjusted for sex; age; race/ethnicity; education; marital status; muscle-strengthening category; smoking status; alcohol consumption; body mass index; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease, and asthma; influenza and pneumococcal vaccination status; and light- and moderate-intensity aerobic physical activity (min/week).

**Table S7. Hazard Ratios for Influenza and Pneumonia Deaths, by Weekly Episodes of Muscle-Strengthening Activity**

MSA (episodes/wk)	Deaths	No. (weighted %)	Person-Years	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	Adjusted HR <sup>b</sup> (95% CI)
0	1355	438 147 (74.4)	4 522 668	1.00 [ref]	1.00 [ref]	1.00 [ref]
1	12	18 236 (3.4)	182 694	0.30 (0.16 to 0.57)	1.03 (0.54 to 1.93)	1.09 (0.58 to 2.05)
2	18	28 519 (5.2)	285 906	0.17 (0.11 to 0.28)	0.51 (0.31 to 0.83)	0.53 (0.33 to 0.87)
3	40	40 996 (7.6)	426 890	0.34 (0.24 to 0.49)	0.93 (0.64 to 1.35)	0.97 (0.67 to 1.41)
4–6	20	27 528 (5.2)	273 241	0.23 (0.14 to 0.38)	0.73 (0.43 to 1.22)	0.76 (0.45 to 1.27)
≥7	71	24 483 (4.3)	239 327	1.01 (0.77 to 1.32)	1.43 (1.07 to 1.90)	1.41 (1.06 to 1.88)

HR, hazard ratio; MSA, muscle-strengthening activity.

Sample adults who participated in the National Health Interview Survey from 1998–2018 and were eligible for linkage to the National Death Index through 2019 (N=577 909).

<sup>a</sup>Adjusted for sex, age, race/ethnicity, education, marital status, and aerobic category.

<sup>b</sup>Adjusted for sex; age; race/ethnicity; education; marital status; smoking status; alcohol consumption; body mass index; presence of heart disease, stroke, hypertension, diabetes, cancer, chronic obstructive pulmonary disease, and asthma; influenza and pneumococcal vaccination status; and aerobic category.